Proven Protection

Proven efficacy in ALK+ advanced NSCLC¹

The longest OS ever reported in ALK+ mNSCLC^1*

Superior DoR vs. crizotinib¹

DoR among Responders:

31.2 months longer with ALECENSA
vs. crizotinib¹

DoR: 31.2 months longer with ALECENSA vs. crizotinib

Lasting efficacy regardless of baseline CNS metastases^1–3

OS:¹

With CNS metastases:

63.4 months with ALECENSA vs. 30.9 months with crizotinib (HR: 0.68; 95% CI: 0.40–1.15)

Without CNS metastases:

94 months with ALECENSA vs. 69.8 months with crizotinib (HR: 0.87; 95% CI: 0.58–1.32)

PFS:³

With CNS metastases:
60% risk reduction with ALECENSA vs. crizotinib (HR: 0.40; 95% CI: 0.25–0.64)

Without CNS metastases:
49% risk reduction with ALECENSA vs. crizotinib (HR: 0.51; 95% CI: 0.33–0.80)

Reducing the risk of CNS progression^3,4

The risk of CNS progression is significantly lower with ALECENSA (12%) vs. crizotinib (45%)^3,4

84% reduction

in the risk of CNS progression

HR: 0.16 (95% CI: 0.10–0.28); p<0.0001.^3,4

ALEX study design

*The ALEX trial was not powered to detect a significant difference in OS.¹

ALK, anaplastic lymphoma kinase; CI, confidence interval; CNS, central nervous system; DoR, duration of response; HR, hazard ratio; mNSCLC, metastatic non-small cell lung cancer; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival.

1. Peters S, et al. Ann Oncol 2025. DOI: 10.1016/j.annonc.2025.09.018. 2. Mok T, et al. Ann Oncol 2020;31:1056–1064. 3. Peters S, et al. N Engl J Med 2017;377:829–838. 4. Peters S, et al. N Engl J Med 2017;377:819–838. Supplementary appendix.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration, or usage in the country of your origin.

FOR HEALTHCARE PROFESSIONALS

Leaving website